FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981992685> ?p ?o ?g. }

• W1981992685 endingPage "S30" @default.
• W1981992685 startingPage "S30" @default.
• W1981992685 abstract "For patients with newly diagnosed rheumatoid arthritis, treatment aim is early, rapid, and sustained remission. We compared the efficacy and safety of strategies initiating the interleukin-6 receptor-blocking monoclonal antibody tocilizumab with or without methotrexate (a conventional synthetic disease-modifying antirheumatic drug [DMARD]), versus initiation of methotrexate monotherapy in line with international guidelines.We did a 2-year, multicentre, randomised, double-blind, double-dummy, strategy study at 21 rheumatology outpatient departments in the Netherlands. We included patients who had been diagnosed with rheumatoid arthritis within 1 year before inclusion, were DMARD-naive, aged 18 years or older, met current rheumatoid arthritis classification criteria, and had a disease activity score assessing 28 joints (DAS28) of at least 2·6. We randomly assigned patients (1:1:1) to start tocilizumab plus methotrexate (the tocilizumab plus methotrexate arm), or tocilizumab plus placebo-methotrexate (the tocilizumab arm), or methotrexate plus placebo-tocilizumab (the methotrexate arm). Tocilizumab was given at 8 mg/kg intravenously every 4 weeks with a maximum of 800 mg per dose. Methotrexate was started at 10 mg per week orally and increased stepwise every 4 weeks by 5 mg to a maximum of 30 mg per week, until remission or dose-limiting toxicity. We did the randomisation using an interactive web response system. Masking was achieved with placebos that were similar in appearance to the active drug; the study physicians, pharmacists, monitors, and patients remained masked during the study, and all assessments were done by masked assessors. Patients not achieving remission on their initial regimen switched from placebo to active treatments; patients in the tocilizumab plus methotrexate arm switched to standard of care therapy (typically methotrexate combined with a tumour necrosis factor inhibitor). When sustained remission was achieved, methotrexate (and placebo-methotrexate) was tapered and stopped, then tocilizumab (and placebo-tocilizumab) was also tapered and stopped. The primary endpoint was the proportion of patients achieving sustained remission (defined as DAS28 <2·6 with a swollen joint count ≤four, persisting for at least 24 weeks) on the initial regimen and during the entire study duration, compared between groups with a two-sided Cochran-Mantel-Haenszel test. Analysis was based on an intention-to-treat method. This trial was registered at ClinicalTrials.gov, number NCT01034137.Between Jan 13, 2010, and July 30, 2012, we recruited and assigned 317 eligible patients to treatment (106 to the tocilizumab plus methotrexate arm, 103 to the tocilizumab arm, and 108 to the methotrexate arm). The study was completed by a similar proportion of patients in the three groups (range 72–78%). The most frequent reasons for dropout were adverse events or intercurrent illness: 27 (34%) of dropouts, and insufficient response: 26 (33%) of dropouts. 91 (86%) of 106 patients in the tocilizumab plus methotrexate arm achieved sustained remission on the initial regimen, compared with 86 (84%) of 103 in the tocilizumab arm, and 48 (44%) of 108 in the methotrexate arm (relative risk [RR] 2·00, 95% CI 1·59–2·51 for tocilizumab plus methotrexate vs methotrexate, and 1·86, 1·48–2·32 for tocilizumab vs methotrexate, p<0·0001 for both comparisons). For the entire study, 91 (86%) of 106 patients in the tocilizumab plus methotrexate arm, 91 (88%) of 103 in the tocilizumab arm, and 83 (77%) of 108 in the methotrexate arm achieved sustained remission (RR 1·13, 95% CI 1·00–1·29, p=0·06 for tocilizumab plus methotrexate vs methotrexate, 1·14, 1·01–1·29, p=0·0356 for tocilizumab vs methotrexate, and p=0·59 for tocilizumab plus methotrexate vs tocilizumab). Nasopharyngitis was the most common adverse event in all three treatment groups, occurring in 38 (36%) of 106 patients in the tocilizumab plus methotrexate arm, 40 (39%) of 103 in the tocilizumab arm, and 37 (34%) of 108 in the methotrexate arm. The occurrence of serious adverse events did not differ between the treatment groups (17 [16%] of 106 patients in the tocilizumab plus methotrexate arm vs 19 [18%] of 103 in the tocilizumab arm and 13 [12%] of 108 in the methotrexate arm), and no deaths occurred during the study.For patients with newly diagnosed rheumatoid arthritis, strategies aimed at sustained remission by immediate initiation of tocilizumab with or without methotrexate are more effective, and with a similar safety profile, compared with initiation of methotrexate in line with current standards.Roche Nederland BV." @default.
• W1981992685 created "2016-06-24" @default.
• W1981992685 creator A5023276710 @default.
• W1981992685 creator A5034387013 @default.
• W1981992685 creator A5039174452 @default.
• W1981992685 creator A5049654213 @default.
• W1981992685 creator A5067328209 @default.
• W1981992685 creator A5070466948 @default.
• W1981992685 creator A5071896405 @default.
• W1981992685 creator A5076070097 @default.
• W1981992685 date "2014-11-01" @default.
• W1981992685 modified "2023-10-06" @default.
• W1981992685 title "Effect of methotrexate on circulating T-helper subsets in rheumatoid arthritis" @default.
• W1981992685 doi "https://doi.org/10.1016/j.injr.2014.10.082" @default.
• W1981992685 hasPublicationYear "2014" @default.
• W1981992685 type Work @default.
• W1981992685 sameAs 1981992685 @default.
• W1981992685 citedByCount "0" @default.
• W1981992685 crossrefType "journal-article" @default.
• W1981992685 hasAuthorship W1981992685A5023276710 @default.
• W1981992685 hasAuthorship W1981992685A5034387013 @default.
• W1981992685 hasAuthorship W1981992685A5039174452 @default.
• W1981992685 hasAuthorship W1981992685A5049654213 @default.
• W1981992685 hasAuthorship W1981992685A5067328209 @default.
• W1981992685 hasAuthorship W1981992685A5070466948 @default.
• W1981992685 hasAuthorship W1981992685A5071896405 @default.
• W1981992685 hasAuthorship W1981992685A5076070097 @default.
• W1981992685 hasBestOaLocation W19819926851 @default.
• W1981992685 hasConcept C126322002 @default.
• W1981992685 hasConcept C141071460 @default.
• W1981992685 hasConcept C142724271 @default.
• W1981992685 hasConcept C198451711 @default.
• W1981992685 hasConcept C204787440 @default.
• W1981992685 hasConcept C27081682 @default.
• W1981992685 hasConcept C2777178219 @default.
• W1981992685 hasConcept C2777575956 @default.
• W1981992685 hasConcept C2781059491 @default.
• W1981992685 hasConcept C2781413609 @default.
• W1981992685 hasConcept C71924100 @default.
• W1981992685 hasConceptScore W1981992685C126322002 @default.
• W1981992685 hasConceptScore W1981992685C141071460 @default.
• W1981992685 hasConceptScore W1981992685C142724271 @default.
• W1981992685 hasConceptScore W1981992685C198451711 @default.
• W1981992685 hasConceptScore W1981992685C204787440 @default.
• W1981992685 hasConceptScore W1981992685C27081682 @default.
• W1981992685 hasConceptScore W1981992685C2777178219 @default.
• W1981992685 hasConceptScore W1981992685C2777575956 @default.
• W1981992685 hasConceptScore W1981992685C2781059491 @default.
• W1981992685 hasConceptScore W1981992685C2781413609 @default.
• W1981992685 hasConceptScore W1981992685C71924100 @default.
• W1981992685 hasLocation W19819926851 @default.
• W1981992685 hasOpenAccess W1981992685 @default.
• W1981992685 hasPrimaryLocation W19819926851 @default.
• W1981992685 hasRelatedWork W189077404 @default.
• W1981992685 hasRelatedWork W1987294331 @default.
• W1981992685 hasRelatedWork W2071054988 @default.
• W1981992685 hasRelatedWork W2096960896 @default.
• W1981992685 hasRelatedWork W2736593664 @default.
• W1981992685 hasRelatedWork W2766107824 @default.
• W1981992685 hasRelatedWork W2783466784 @default.
• W1981992685 hasRelatedWork W2970100988 @default.
• W1981992685 hasRelatedWork W2996380604 @default.
• W1981992685 hasRelatedWork W4283269884 @default.
• W1981992685 hasVolume "9" @default.
• W1981992685 isParatext "false" @default.
• W1981992685 isRetracted "false" @default.
• W1981992685 magId "1981992685" @default.
• W1981992685 workType "article" @default.